Quizartinib

Quizartinib is a member of the class of phenylureas that is urea in which one of the amino groups has been substituted by a 5-tert-butyl-1,2-oxazol-3-yl group while the other has been substituted by a phenyl group substituted at the para- position by an imidazo[2,1-b][1,3]benzothiazol-2-yl group that, in turn, is substituted at position 7 by a 2-(morpholin-4-yl)ethoxy group. Among its listed roles, it functions as a necroptosis inhibitor, an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It belongs to the class of phenylureas, a member of morpholines, a benzoimidazothiazole and a member of isoxazoles. It is grouped under the following drug class(es): Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include N-(5-tert-Butylisoxazol-3-yl)-N’-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2, 1-b][1 and 3]benzothiazol-2-yl]phenyl}urea MFCD18074524. Its PubChem CID is 24889392.